Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Nov-2020
Document Type: USP Monographs
DocId: GUID-C7BA6F7D-3D05-47E5-96CC-7EE91B7C9AB3_2_en-US
DOI: https://doi.org/10.31003/USPNF_M20544_02_01
DOI Ref: xo4wp

© 2025 USPC
Do not distribute

Cromolyn Sodium Nasal Solution

DEFINITION

Change to read:

Cromolyn Sodium Nasal Solution is an aqueous solution of Cromolyn Sodium. It contains NLT 90.0% and NMT 110.0% of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$). It may contain suitable ▲antimicrobial and stabilizing agents.▲ (USP 1-Aug-2020)

IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution,* as obtained in the *Assay*.

Add the following:

▲• **B.** The UV absorption spectrum of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution,* as obtained in the *Assay*.▲ (USP 1-Aug-2020)

ASSAY

Change to read:

• **Procedure**

Buffer: 5.6 g/L of monobasic potassium phosphate and 22.2 g/L of myristyltrimethylammonium bromide in water. Adjust with ▲50% sodium hydroxide TS▲ (USP 1-Aug-2020) to a pH of 6.5.

Mobile phase: Methanol and *Buffer* (55:45)

Diluent: Acetonitrile and water (30:70)

System suitability solution: 0.5 mg/mL of USP Cromolyn Sodium RS and 0.02 mg/mL each of USP Cromolyn Related Compound A RS and USP Cromolyn Related Compound B RS in *Diluent*

Standard solution: 0.5 mg/mL of USP Cromolyn Sodium RS in *Diluent*. Sonication may be needed to aid dissolution.

Sample solution: Nominally equivalent to 0.5 mg/mL of cromolyn sodium from a volume of Nasal Solution in *Diluent*

Chromatographic system

(See *Chromatography (621), System Suitability*.)

Mode: LC

Detector: UV 326 nm. ▲For *Identification B*, use a diode array detector in the range of 220–400 nm.▲ (USP 1-Aug-2020)

Column: 4.6-mm × 10-cm; 3.5-µm packing L7

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 µL

▲**Run time:** NLT 2 times the retention time of cromolyn▲ (USP 1-Aug-2020)

System suitability

Samples: *System suitability solution* and *Standard solution*

[Note—See *Table 1* for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; NLT 2.0 between cromolyn related compound A and cromolyn, *System suitability solution*

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$) in the portion of Nasal Solution taken:

OFFICIAL
Documents
Document Sharing Hub
Full document details: Cromolyn Sodium Nasal Solution

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

C_S = concentration of USP Cromolyn Sodium RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

Change to read:

• **Organic Impurities**

Mobile phase, Diluent, and **System suitability solution:** Prepare as directed in the *Assay*.

Standard solution: 0.002 mg/mL each of USP Cromolyn Related Compound A RS, USP Cromolyn Related Compound B RS, and USP Cromolyn Sodium RS in *Diluent*

Sample solution: Nominally equivalent to 2 mg/mL of cromolyn sodium from a volume of Nasal Solution in *Diluent*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 326 nm

Column: 4.6-mm × 10-cm; 3.5-µm packing L7

Temperatures

Autosampler: 4°

Column: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 µL

Run time: ▲NLT▲ (USP 1-Aug-2020) 2 times the retention time of cromolyn

System suitability

Samples: *System suitability solution* and *Standard solution*

▲[Note—See *Table 1* for the relative retention times.]▲ (USP 1-Aug-2020)

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; NLT 2.0 between cromolyn related compound A and cromolyn, *System suitability solution*

Relative standard deviation: NMT 3% for 6 replicate injections for each peak, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of cromolyn related compound A or cromolyn related compound B in the portion of Nasal Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn related compound A or cromolyn related compound B from the *Sample solution*

r_S = peak response of cromolyn related compound A or cromolyn related compound B from the *Standard solution*

C_S = concentration of ▲USP Cromolyn Related Compound A RS or USP Cromolyn Related Compound B RS▲ (USP 1-Aug-2020) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified degradation product in the portion of Nasal Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each ▲individual▲ (USP 1-Aug-2020) unspecified degradation product from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

OFFICIAL

AVA Documents Document Sharing Hub